Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Small Molecule Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IDO1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human IDO1 Protein (Active) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active enzyme for high-throughput screening. |
View IDO1 Products |
| Gene Delivery | IDO1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and cellular kynurenine assays. |
View IDO1 Products |
| Benchmark Ab | Anti-IDO1 Recombinant Antibody High-affinity clone for western blot, IHC, and flow cytometry validation. |
View IDO1 Products |
| Validator | IDO1 siRNA Set For knockdown verification in tumor/dendritic cell co-cultures. |
View IDO1 Products |
| Related Target A | TDO2 (Tryptophan 2,3-dioxygenase) Crucial for selectivity profiling; prevents off-target liabilities in the kynurenine pathway. |
View TDO2 Products |
| Related Target B | AhR (Aryl Hydrocarbon Receptor) Downstream transcription factor activated by kynurenine; key readout for pathway inhibition. |
View AhR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against TDO2 | Highly active Human TDO2 and IDO1 recombinant proteins available for parallel enzymatic screening. |
| Cell-based kynurenine assay optimization | Lentiviral vectors optimized for robust, stable expression of IDO1 in HEK293 or tumor cell lines. |
| Lack of Controls | Sequence-verified benchmark antibodies and validated siRNA sets included for target validation. |
| False Positives in Enzymatic Assays | High-purity, endotoxin-controlled proteins minimize assay interference and false hits. |
Live IDO1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IDO1 therapeutics is intensifying, with major players shifting focus from traditional small-molecule catalytic inhibitors to targeted protein degraders (PROTACs) and dual-targeting strategies. As first-generation therapies like Epacadostat undergo re-evaluation in specific combination regimens, the next wave of R&&D is targeting dual IDO1/TDO inhibitors and downstream AhR pathway modulation to overcome immune evasion in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Incyte, BMS, Roche | Solid Tumors, Melanoma | Enzymatic Activity Assay (Need highly active, pure IDO1/TDO2 proteins) |
| PROTACs / Degraders | Arvinas, Cullgen | Refractory Cancers | Degradation kinetics (Need stable IDO1-expressing cell lines via Lentivirus) |
| Dual IDO1/TDO Inhibitors | IO Biotech, Domain Therapeutics | Advanced Malignancies | Selectivity & Cross-reactivity Panel (Need comparative recombinant proteins) |